Please assess the completion status of the following clinical trial:

Trial Title: CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Type 2 diabetes~2. Elevated glycosylated haemoglobin (HbA1c): 6.5 - 8.5%, inclusive, if treatment naïve or mono-/dual therapy with metformin and/or an alpha-glucosidase inhibitor; 6.5 - 7.5%, inclusive, if treatment with sulphonylurea/glinide in mono- or dual (with metformin OR an alpha-glucosidase inhibitor) therapy)~3. Pre-existing cardiovascular disease OR specified diabetes end-organ damage OR age =\> 70 years OR two or more specified cardiovascular risk factor~4. BMI =\< 45kg/m²~5. age between \>= 40 and =\< 85 years~6. signed and dated written International Conference of Harmonisation( ICF)~7. stable anti-diabetic background for at least 8 wks before study start~Exclusion criteria:~1. Type 1 diabetes~2. Treatment with other antidiabetic drugs (e.g. rosiglitazone, pioglitazone, Glucagon-like peptide 1 (GLP-1) analogue/agonists, Dipeptidyl-peptidase IV (DPP-IV) inhibitors or any insulin) prior to informed consent (previous short term use of insulin (up to two weeks) is allowed if taken at least 8 weeks prior informed consent)~3. treatment with any anti-obesity drug less than 3 months before ICF~4. uncontrolled hyperglycemia~5. previous or planned bariatric surgery or intervention~6. current or planned system corticoid treatment~7. change in thyroid hormones treatment~8. acute liver disease or impaired hepatic function~9. pre-planned coronary artery revascularization within 6 months of ICF~10. known hypersensitivity to any of the components~11. Inappropriateness of glimepiride treatment for renal safety issues according to local prescribing information~12. congestive heart failure class III or IV~13. acute or chronic metabolic acidosis~14. hereditary galactose intolerance~15. alcohol or drug abuse~16. participation in another trail with IMP given 2 months before Investigational Medicinal/Medical Product (IMP) start~17. pre-menopausal women who are nursing or pregnant or of child-bearing potential and not willing to use acceptable method of birth control~18. patients considered reliable by the investigator~19. acute coronary syndrome =\< 6 wks before ICF~20. stroke or Transient Ischemic Attack (TIA) =\< 3 months prior to ICF

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- linagliptin (Type: EXPERIMENTAL): patient to receive linagliptin or glimepiride placebo over encapsulated tablet Quaque die (QD)
- glimepiride 1-4 mg QD (Type: ACTIVE_COMPARATOR): patient to receive glimepiride 1-4 mg or linagliptin placebo tablet Quaque die (QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).